NIIMBL Roadmaps: 1. Vaccines: 2. Antibody-Drug Conjugates (ADC) and Bi-specific Antibodies: 3. Gene Therapies

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) collaborated with BioPhorum to create and publish three technology roadmaps to complement Biophorum’s Biomanufacturing Technology Roadmap published in 2017.

The roadmaps developed in a collaboration between NIIMBL and Biophorum aim to further technology innovation in the US biopharmaceutical industry. The roadmaps, covering Vaccines, Gene Therapy and Antibody-Drug Conjugates/ Bispecific antibodies, were developed using the highly successful roadmapping process that led to the first edition of the BioPhorum Biomanufacturing Technology Roadmap.

The roadmaps represent the view of multiple US industry stakeholders including biomanufacturers, suppliers, academics and government agencies and are intended as a starting point for cross industry dialogue and engagement. The documents highlight the manufacturing challenges, technology needs and areas of opportunity in each of the three product categories with additional focus on US regulatory and workforce challenges. The topics were selected to complement BioPhorum’s Biomanufacturing Technology Roadmap.

“Through these roadmaps, we set out to create a clear vision of innovation for biopharmaceutical manufacturing processes and platforms that will ultimately enhance access to the medicines that have the ability to improve and save lives,” said Kelvin Lee, NIIMBL Institute Director

“We are delighted to have facilitated the development and publication of the first three NIIMBL roadmaps,” said Steve Jones, BioPhorum Director. “Together with the BioPhorum Biomanufacturing Technology Roadmap, these documents will inform biomanufacturing technology development in the US and worldwide for the next decade and beyond. We look forward to continuing this roadmap collaboration with the NIIMBL community.”

This deliverable has been published via the NIIMBL website.

Read the full publication